I will be watching the medical research publications to see what sort of peer reviews and opinions are presented on the potential of creating successful treatments from mesenchymoangioblast derived stem cells.
The key to this company may be the differentiation between Mesenchymal stem cells and their precursor, mesenchymoangioblasts.
If mesenchymoangioblast derived stem cells prove to be superior in every way to Mesenchymal derived stem cells, then this company will become a major force. It is a big IF though at the moment.
If mesenchymoangioblast derived stem cells prove ineffective, then the company dies.
These processes will take many years to research and validate.
Stem Cell research however, is booming, and there are not too many ASX stocks in the area. A couple of others are MSB, BNO and ANP.
You are right about the shares on issue once Cynata is taken out, there will be a couple of billion, but I think they plan to do a consolidation on the close of EcoQuest and the rebadging as Cynata, which may be a good time to consider them because you will know the share structure, and you will have had another year of mesenchymoangioblast research.
They have given themselves 18 months to take out Cynata, and they are going to need more cash before they do that.
Unlike some other holders here, I do think it will retrace to about 1 cent, but we are all entitled to our opinions, because none of us really knows. I will buy a few more at a cent, but not a lot at this time.
So it is one of those long.. long.. punts, but hey, after doing the research, and talking to the folks at Cynata, it is something you can throw a few pennies at, keep an eye on, and wait and see - who knows.
Gw
ECQ Price at posting:
1.6¢ Sentiment: LT Buy Disclosure: Held
